Tom Taghon
- Immunology top 1%
- Immune Cell Function and Interaction 48
- T-cell and B-cell Immunology 42
- Immunotherapy and Immune Responses 19
- Cancer Research top 2%
- MicroRNA in disease regulation 10
- Hematology top 2%
- Molecular Biology top 5%
- RNA modifications and cancer 12
- Epigenetics and DNA Methylation 10
- Developmental Biology and Gene Regulation 10
- Oncology top 5%
- CAR-T cell therapy research 25
- Co-authors
- Ellen V. RothenbergGeorges LeclercqBart VandekerckhoveJean PlumMary A. YuiMagda De SmedtInge Van de WallePieter Van Vlierberghe
- Cited by
- ImmunologyCancer ResearchHematology
- Partner nations
- BelgiumUnited StatesNetherlands
In The Last Decade
Tom Taghon
104 papers receiving 3.8k citations
Peers
Comparison fields: 5 of 103
- Immunology 1.8k
- Cancer Research 668
- Hematology 480
- Molecular Biology 2.1k
- Oncology 776
Countries citing papers authored by Tom Taghon
This map shows the geographic impact of Tom Taghon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Taghon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Taghon more than expected).
Fields of papers citing papers by Tom Taghon
This network shows the impact of papers produced by Tom Taghon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Taghon. The network helps show where Tom Taghon may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tom Taghon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 6 | |
| 6 | 2022 | 3 | |
| 7 | 2022 | 8 | |
| 8 | 2020 | 44 | |
| 9 | 2020 | 27 | |
| 10 | 2020 | 25 | |
| 11 | 2018 | 24 | |
| 12 | 2016 | 30 | |
| 13 | 2014 | 6 | |
| 14 | 2013 | 20 | |
| 15 | 2012 | 39 | |
| 16 | 2011 | 67 | |
| 17 | 2009 | 40 | |
| 18 | 2009 | 143 | |
| 19 | 2002 | 87 | |
| 20 | 2001 | 33 |
About Tom Taghon
Tom Taghon is a scholar working on Immunology, Hematology, Oncology, Cancer Research and Molecular Biology, having authored 106 papers that have together received 3.8k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (48 papers), T-cell and B-cell Immunology (42 papers), CAR-T cell therapy research (25 papers), Immunotherapy and Immune Responses (19 papers), RNA modifications and cancer (12 papers), MicroRNA in disease regulation (10 papers), Epigenetics and DNA Methylation (10 papers) and Developmental Biology and Gene Regulation (10 papers). The work is most often cited by research in Immunology (1.8k citations), Cancer Research (668 citations), Hematology (480 citations), Molecular Biology (2.1k citations) and Oncology (776 citations). Tom Taghon has collaborated with scholars based in Belgium, United States and Netherlands. Frequent co-authors include Ellen V. Rothenberg, Georges Leclercq, Bart Vandekerckhove, Jean Plum, Mary A. Yui, Magda De Smedt, Inge Van de Walle, Pieter Van Vlierberghe, Tessa Kerre and Rochelle A. Diamond. Their work appears in journals such as Blood, Haematologica, Frontiers in Immunology, The Journal of Immunology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.